Loading
Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system.
Josep Llovet was principal investigator of SHARP, the 2008 trial showing sorafenib improves survival in advanced hepatocellular carcinoma, the first systemic therapy to do so, and co-created the Barcelona Clinic Liver Cancer staging and treatment algorithm used worldwide. His laboratory defined the molecular classes of HCC and he has led guidelines for the EASL and AASLD. He continues to work on biomarkers for immunotherapy in liver cancer. Alongside the Mount Sinai directorship he leads the Translational Research in Hepatic Oncology group at IDIBAPS, Hospital Clínic de Barcelona, and is among the most cited researchers in hepatocellular carcinoma.
| Title | Journal | Year |
|---|---|---|
| Sorafenib in advanced hepatocellular carcinoma (SHARP) | NEJM | 2008 |
| Hepatocellular carcinoma | Nature Reviews Disease Primers | 2021 |
| Hepatocellular carcinoma | Nature Reviews Disease Primers | 2016 |
Shares Hospital Clínic de Barcelona / IDIBAPS, Hepatocellular carcinoma and the tags hcc, trialist.
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Hepatocellular carcinoma.
Shares Hepatocellular carcinoma, Small-molecule kinase inhibitors and the tags hcc, trialist.
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Hepatocellular carcinoma.
Shares Hospital Clínic de Barcelona / IDIBAPS and the tag clinician-scientist.
Shares Hepatocellular carcinoma and the tags clinician-scientist, liver cancer.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags clinician-scientist, liver cancer.